Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax.
about
RaxibacumabMonoclonal antibody-based therapies for microbial diseasesAntitoxin Treatment of Inhalation Anthrax: A Systematic ReviewPrinciples of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agentsPassive Immunotherapy Protects against Enteric Invasion and Lethal Sepsis in a Murine Model of Gastrointestinal AnthraxThe effects of anthrax lethal toxin on host barrier functionEngineered single-domain antibodies with high protease resistance and thermal stabilityMedical countermeasures for unwanted CBRN exposures: Part I chemical and biological threats with review of recent countermeasure patents.Anthrax toxin-neutralizing antibody reconfigures the protective antigen heptamer into a supercomplex.A chimeric protein that functions as both an anthrax dual-target antitoxin and a trivalent vaccine.A FRET-based high throughput screening assay to identify inhibitors of anthrax protective antigen binding to capillary morphogenesis gene 2 proteinReceptors of anthrax toxin and cell entry.Cyclodextrin derivatives as anti-infectives.Cargo-delivery platforms for targeted delivery of inhibitor cargos against botulism.Production of Functionally Active and Immunogenic Non-Glycosylated Protective Antigen from Bacillus anthracis in Nicotiana benthamiana by Co-Expression with Peptide-N-Glycosidase F (PNGase F) of Flavobacterium meningosepticum.Combinations of monoclonal antibodies to anthrax toxin manifest new properties in neutralization assays.Targeted Treatment for Bacterial Infections: Prospects for Pathogen-Specific Antibiotics Coupled with Rapid DiagnosticsSmall-molecule inhibitors of lethal factor protease activity protect against anthrax infection.Obiltoxaximab: Adding to the Treatment Arsenal for Bacillus anthracis Infection.Emerging insights into the biology of typhoid toxin.Injection anthrax--a new outbreak in heroin usersRaxibacumab for inhalational anthrax: an effective specific therapeutic approach?
P2860
Q24644111-362E1D66-856A-4BCA-8F26-D084A2EC9FACQ27490830-792DB67A-C2E3-4C00-9A76-D83C5FD9C5C5Q28383765-4CB38F80-8778-4DFB-A57C-A54475F8D9BAQ28384852-8C04D9F3-93A5-4ED3-8570-214577ECC0D1Q28392599-B085298E-414F-4D5D-8569-C15B7E513EDCQ28393062-21590CF3-473A-460F-A86D-044DA384FFFDQ28478199-EE80A873-5D74-49DA-B0D8-49FCC64813F4Q30245600-6556988E-7CFF-480E-8CCA-983B830E3F64Q34069693-0BB9F3B2-A247-450B-985F-C5EB2BAC9808Q34289944-DFD2EA17-4571-4236-B8D0-D594650F2303Q34328401-8BAF5535-471B-4C1C-AE5B-393134B2DC47Q34659076-366F50DD-E1FC-4A00-92C5-6CA36A8C2F54Q34980556-AA938F43-A4D5-46DF-83C2-9D48EF28CB73Q35542237-3E0CE0E5-8672-4C49-B426-2C6BE7AD19A6Q35996281-5B0D8340-6047-4994-A47B-E3A2E5CEE26AQ36911369-69AD18DB-6984-43E7-8B72-1BC23DDD7340Q37087480-3EED0936-F5EB-48D3-88ED-13123E72538BQ37124221-73D2A083-967D-4FB6-8BDB-BCD9C7FB4B8FQ38749263-F6A66575-BEA1-4507-92A9-249AFC8F78AFQ39141220-9C6EF233-F85A-49BA-96B7-F3503C291FA8Q41958922-A46B4D06-52AA-4612-A90C-B4073E25410BQ43070082-4A3F1EAF-0967-463F-A56A-A8C0187CB149
P2860
Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax.
@en
Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax.
@nl
type
label
Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax.
@en
Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax.
@nl
prefLabel
Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax.
@en
Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax.
@nl
P2860
P356
P1433
P1476
Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax.
@en
P2093
Anette Schneemann
P2860
P356
10.2217/17460913.4.1.35
P577
2009-02-01T00:00:00Z